Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ambry Genetics | RCV002389173 | SCV002702275 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-04-03 | criteria provided, single submitter | clinical testing | The p.I467L variant (also known as c.1399A>T), located in coding exon 9 of the BRIP1 gene, results from an A to T substitution at nucleotide position 1399. The isoleucine at codon 467 is replaced by leucine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Labcorp Genetics |
RCV003095087 | SCV003323199 | uncertain significance | Familial cancer of breast; Fanconi anemia complementation group J | 2022-03-11 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. This variant has not been reported in the literature in individuals affected with BRIP1-related conditions. This variant is not present in population databases (gnomAD no frequency). This sequence change replaces isoleucine, which is neutral and non-polar, with leucine, which is neutral and non-polar, at codon 467 of the BRIP1 protein (p.Ile467Leu). |